Overview

Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)

Status:
Completed

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of the fix-dose combination therapy with Gemigliptin 50mg and Rosuvastatin 20mg with type 2 diabetes and dyslipidemia

Phase:

Phase 3

Details

Lead Sponsor:

LG Life Sciences

Treatments:

Rosuvastatin Calcium